Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles (Q33813145)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

10

object named as

M Juliana McElrath

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

David C. Montefiori

5

object named as

David C Montefiori

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

21

object named as

Bernard Moss

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Lindsey R Baden

12

object named as

Lindsey R Baden

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

18

object named as

Beryl A Koblin

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Susan Buchbinder

16

object named as

Susan P Buchbinder

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Mark J Mulligan

15

object named as

Mark J Mulligan

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Georgia D. Tomaras

4

object named as

Georgia D Tomaras

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Scott M. Hammer

17

object named as

Scott M Hammer

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Harriet L Robinson

22

object named as

Harriet L Robinson

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Spyros A Kalams

9

object named as

Spyros A Kalams

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

object named as

Kelly Seaton

3

0 references

author name string

Paul A Goepfert

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Marnie L Elizaga

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Alicia Sato

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

John Hural

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Stephen C DeRosa

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Michael C Keefer

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Javier R Lama

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jorge Sanchez

14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Michael Pensiero

19

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Chris Butler

20

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

HVTN 205 Study Group

23

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network

24

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

7 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Journal of Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

210

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

99-110

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Targeting of conserved gag-epitopes in early HIV infection is associated with lower plasma viral load and slower CD4(+) T cell depletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Non-neutralizing antibodies in prevention of HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Emerging concepts on the role of innate immunity in the prevention and control of HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

HIV-specific gag responses in early infancy correlate with clinical outcome and inversely with viral load

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Translating innate immunity into immunological memory: implications for vaccine development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNF-alpha in oligodendrocytes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Humoral immunity due to long-lived plasma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4072895

4 July 2018

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU003

21 January 2018

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU003

21 January 2018

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU003

21 January 2018

Performance comparison of two commercial BGO-based PET/CT scanners using NEMA NU 2-2001.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU003

21 January 2018

Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU003

21 January 2018

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU003

21 January 2018

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU003

21 January 2018

AIDS research. More woes for struggling HIV vaccine field

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU003

21 January 2018

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU003

21 January 2018

Identifiers

10.1093/INFDIS/JIU003

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33813145&oldid=1953514518"